GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (LTS:0R6Y) » Definitions » Institutional Ownership

Thor Medical ASA (LTS:0R6Y) Institutional Ownership : 0.26% (As of May. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Thor Medical ASA's institutional ownership is 0.26%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Thor Medical ASA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Thor Medical ASA's Float Percentage Of Total Shares Outstanding is 0.00%.


Thor Medical ASA Institutional Ownership Historical Data

The historical data trend for Thor Medical ASA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA Institutional Ownership Chart

Thor Medical ASA Historical Data

The historical data trend for Thor Medical ASA can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.26

Thor Medical ASA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Thor Medical ASA (LTS:0R6Y) Business Description

Traded in Other Exchanges
Address
Kjelsasveien 168 B, Oslo, NOR, 0884
Nordic Nanovector ASA is a biopharmaceutical company. It is engaged in the development and commercialization of targeted therapeutics to improve the lives of patients with haematological cancers, such as non-Hodgkin lymphoma and leukaemia. The company's main clinical stage product is Betalutin.

Thor Medical ASA (LTS:0R6Y) Headlines

No Headlines